Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy
SAN MARINO, Calif., Oct. 12 /PRNewswire/ -- Epeius
Biotechnologies Corporation today announced more stunning results
of its pioneering clinical studies of Rexin-G, the world's first
and, so far only, tumor-targeted genetic medicine to be validated
in the clinic. Administered as stand-alone therapy in late-stage
cases of chemotherapy-resistant cancer, Rexin-G has once again
accomplished what standard cancer treatments and even much-touted
biologics have failed to do: that is, to bring forth the benefits
of remission in otherwise intractable metastatic cancers. Three
recent cases of Stage IV metastatic cancer, namely (i)
osteosarcoma, (ii) prostate cancer, and (iii) pancreas cancer,
demonstrated that Rexin-G treatments alone led to clinical
remission of disease in each of these poor prognosis patients. Even
more remarkable, perhaps, are the profiles of the latter two
patients, which signal the advent of Rexin-G as the vanguard of a
new class of exceedingly precise, selective, and effective
anti-cancer agents, and which typify a newfound societal acceptance
and acknowledgement of the real-world promise and potential of this
uniquely-targeted genetic medicine.
Remarkably, a Catholic priest, who was previously bedridden and
in withering pain, suffering from end-stage prostate cancer that
had spread to his bones, received successive courses of Rexin-G,
during which time the bone pain was relieved, the PSA tumor markers
fell, the bone tumors stopped growing, and even the previously
inoperable primary tumor disappeared on follow-up CT scans. As the
priest's bones began to heal and strengthen, he arose from his bed
and is currently saying daily Mass and delivering lectures in the
seminary. What is even more remarkable is that this revered man of
the cloth was over ninety years old at the time of his treatment
and remission. This past week, the latest good news comes from the
trenches of Stage IVb pancreas cancer, where a complete clinical
remission was documented in a patient undergoing Rexin-G treatment
as stand-alone therapy in an ongoing U.S. Phase I/II clinical
trial.
According to Erlinda Maria Gordon, M.D., Medical Director of
Epeius Biotech, "It is gratifying to learn that more and more
eminent medical oncologists around the world are recommending
Rexin-G as 'Best Care' for patients with refractory metastatic
disease, and even more gratifying to show how truly effective
Rexin-G at these doses can be in eradicating such difficult
cancers." Indeed, as the unprecedented single-agent efficacy of
Rexin-G is incontrovertibly demonstrated in an increasing number of
chemo-resistant cancers, the progressive steps of these intrepid
pioneers may provide a rational basis of hope and expectation for
many when standard therapy has failed. Rexin-G is approved for the
treatment of all solid tumors in the Philippines, and has been
granted both Orphan Drug Status for pancreas cancer, osteosarcoma
and soft tissue sarcoma, and Fast Track Designation for pancreas
cancer by the U.S. FDA.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held
biopharmaceutical company dedicated to the advancement of genetic
medicine with the development and commercialization of its
proprietary targeted delivery systems. To learn more about our
pipeline of proprietary biotechnologies currently available for
clinical development and/or new product development, please visit
us at http://www.epeiusbiotech.com/.
*(Logo Link:
Send2Press.com/mediaboom/09-1012-EpeiusBio_300dpi.jpg)
This release was issued on behalf of the above organization by
Send2Press(R), a unit of Neotrope(R). http://www.send2press.com/
Note to editors: Additional Epeius news/RSS: http://profiles.send2press.com/Epeius_Biotechnologies.shtml
Source: Epeius Biotechnologies Corporation
CONTACT: Erlinda M. Gordon, M.D. of Epeius Biotechnologies
Corporation,
+1-626-441-6695, egordon@epeiusbiotech.com
Web Site: http://www.epeiusbiotech.com/
Posted: October 2009
